Chemical Namepolatuzumab vedotin-piiq
Dosage FormInjectable (intravenous; 140 mg/vial)
Drug ClassMiscellaneous antineoplastics
CompanyGenentech Inc.
Approval Year2019


  • Polivy is indicated in combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, after at least two prior therapies.
Last updated on 10/26/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Polivy (polatuzumab vedotin-piiq) Prescribing Information2019Genentech Inc.